Affiliation:
1. EPI‐PHARE (French National Agency for Medicines and Health Products Safety [ANSM] and French National Health Insurance [CNAM]) Saint‐Denis France
2. Center for Research Epidemiology and Population Health (CESP), Radiation Epidemiology Team Université Paris‐Saclay, Université Paris‐Sud, UVSQ Villejuif France
3. Faculté de Pharmacie Université Paris‐Saclay Châtenay‐Malabry France
4. Anti Infective Evasion and Pharmacoepidemiology Center for Research Epidemiology and Population Health (CESP) Montigny‐le‐Bretonneu France
Abstract
Background
Since July 2018, numerous lots of valsartan have been found to be contaminated with
N
‐nitrosodimethylamine (NDMA). We aimed to assess the association between exposure to valsartan products contaminated with NDMA and the risk of cancer.
Methods and Results
This study was based on data from the Système National des Données de Santé, which is a national database that includes all French residents' health‐related expenses. The target population was consumers of valsartan between January 1, 2013 and December 31, 2017, aged between 40 and 80 years old. The association of exposure to contaminated valsartan with the occurrence of any malignancy and cancer by location was evaluated by fitting Cox proportional hazards models weighted by the inverse probability of treatment. A total of 1.4 million subjects without any history of cancer were included. A total of 986 126 and 670 388 patients were exposed to NDMA‐contaminated and uncontaminated valsartan, respectively. The use of the NDMA‐contaminated valsartan did not increase the overall risk of cancer (adjusted hazard ratio [aHR], 0.99 [95% CI, 0.98–1.0]). However, exposed patients had a higher risk of liver cancer (aHR, 1.12 [95% CI, 1.04–1.22]) and melanoma (aHR, 1.10 [95% CI, 1.03–1.18]). We estimated a mean of 3.7 and 5.8 extra cases per year per 100 000 person‐years of liver cancer and melanoma, respectively.
Conclusions
Our study was the largest to date to examine cancer risks associated with exposure to NDMA‐contaminated valsartan. Our findings suggest a slight increased risk of liver cancer and melanoma in patients exposed to NDMA in regularly taken medications.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Cardiology and Cardiovascular Medicine
Reference48 articles.
1. Valsartan
2. French National Agency for Medicines and Health Products Safety
. New valsartan medicine recalls: List of medicines concerned. Available at: https://ansm.sante.fr/uploads/2021/01/08/2019‐05‐29‐liste‐sartans‐concernes.pdf. 2019.
3. The contamination of valsartan and other sartans, Part 2: Untargeted screening reveals contamination with amides additionally to known nitrosamine impurities
4. Use of N-nitrosodimethylamine (NDMA) contaminated valsartan products and risk of cancer: Danish nationwide cohort study
5. US Environmental Protection Agency (EPA). Technical Fact Sheet – NDMA. Washington, DC: US Environmental Protection Agency. Available at: https://www.epa.gov/sites/production/files/2017‐10/documents/ndma_fact_sheet_update_9‐15‐17_508.pdf; 2017.